These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11910959)

  • 21. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
    Patzer JA; Dzierzanowska D; Turner PJ
    J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of antimicrobial activity of beta-lactam antibiotics using Etest against clinical isolates from 60 medical centres in Japan.
    Ishii Y; Alba J; Kimura S; Shiroto K; Yamaguchi K
    Int J Antimicrob Agents; 2005 Apr; 25(4):296-301. PubMed ID: 15784308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
    Morrissey I; Ge Y; Janes R
    Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in antimicrobial resistance among today's bacterial pathogens.
    Thornsberry C
    Pharmacotherapy; 1995; 15(1 Pt 2):3S-8S. PubMed ID: 7753690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007.
    Guembe M; Cercenado E; Alcalá L; Marín M; Insa R; Bouza E
    Rev Esp Quimioter; 2008 Sep; 21(3):166-73. PubMed ID: 18792817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia.
    Kader AA; Angamuthu K
    Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Samaha-Kfoury JN; Kanj SS; Araj GF
    Am J Infect Control; 2005 Apr; 33(3):134-6. PubMed ID: 15798666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia Rodríguez JA; Martin R; Soria G; Zapardiel J;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):317-23. PubMed ID: 10668591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.